FI920771A0 - Hydroxylamidbaserade kollagenasinhibitorer. - Google Patents

Hydroxylamidbaserade kollagenasinhibitorer.

Info

Publication number
FI920771A0
FI920771A0 FI920771A FI920771A FI920771A0 FI 920771 A0 FI920771 A0 FI 920771A0 FI 920771 A FI920771 A FI 920771A FI 920771 A FI920771 A FI 920771A FI 920771 A0 FI920771 A0 FI 920771A0
Authority
FI
Finland
Prior art keywords
hydroxylamid
collagenasin
inhibitor
base
disease
Prior art date
Application number
FI920771A
Other languages
English (en)
Finnish (fi)
Inventor
Colin Campion
Alan Hornsby Davidson
Jonathan Philip Dickens
Michael John Crimmin
Original Assignee
British Bio Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Bio Technology filed Critical British Bio Technology
Publication of FI920771A0 publication Critical patent/FI920771A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
FI920771A 1989-08-24 1992-02-21 Hydroxylamidbaserade kollagenasinhibitorer. FI920771A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898919251A GB8919251D0 (en) 1989-08-24 1989-08-24 Compounds
PCT/GB1990/001117 WO1991002716A2 (en) 1989-08-24 1990-07-20 Hydroxamic acid based collagenase inhibitors

Publications (1)

Publication Number Publication Date
FI920771A0 true FI920771A0 (fi) 1992-02-21

Family

ID=10662057

Family Applications (1)

Application Number Title Priority Date Filing Date
FI920771A FI920771A0 (fi) 1989-08-24 1992-02-21 Hydroxylamidbaserade kollagenasinhibitorer.

Country Status (16)

Country Link
US (2) US5453438A (ko)
EP (1) EP0489032B1 (ko)
JP (1) JP2871849B2 (ko)
KR (1) KR927003624A (ko)
AT (1) ATE111443T1 (ko)
AU (1) AU639706B2 (ko)
CA (1) CA2064786A1 (ko)
DE (1) DE69012575T2 (ko)
DK (1) DK0489032T3 (ko)
ES (1) ES2063975T3 (ko)
FI (1) FI920771A0 (ko)
GB (1) GB8919251D0 (ko)
NO (1) NO920702L (ko)
NZ (1) NZ235050A (ko)
TW (1) TW202456B (ko)
WO (1) WO1991002716A2 (ko)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5268384A (en) * 1990-11-21 1993-12-07 Galardy Richard E Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5326760A (en) * 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
CA2158352A1 (en) * 1993-03-16 1994-09-29 Michael John Crimmin Hydroxamic acid derivatives as metalloproteinase inhibitors
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ES2134939T3 (es) * 1993-04-27 1999-10-16 Celltech Therapeutics Ltd Derivados de peptidilo como inhibidores de metaloproteinas.
ES2075797B1 (es) * 1993-08-18 1996-05-16 British Bio Technology Derivados de acidos hidroxamicos terapeuticamente activos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
ES2075798B1 (es) * 1993-08-18 1996-03-01 British Bio Technology Derivados de aminoacidos naturales como inhibidores de metaloproteinasas, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y el uso de dichos compuestos en medicina.
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
BR9506535A (pt) * 1994-01-20 1997-09-16 British Biotech Pharm Inibidores de metaloproteinases
GB9501737D0 (en) * 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
US5919940A (en) * 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
NZ322553A (en) 1995-11-23 1998-12-23 British Biotech Pharm Metalloproteinase inhibitors
CA2264045A1 (en) * 1996-08-28 1998-03-05 Randall Stryker Matthews Heterocyclic metalloprotease inhibitors
CN1228772A (zh) 1996-08-28 1999-09-15 普罗克特和甘保尔公司 杂环金属蛋白酶抑制剂
KR20000035918A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 1,3-디헤테로시클릭 메탈로프로테아제 저해제
KR20000035925A (ko) * 1996-08-28 2000-06-26 데이비드 엠 모이어 매트릭스 메탈로프로테아제 저해제인 포스핀산 아미드
ATE272062T1 (de) * 1996-08-28 2004-08-15 Procter & Gamble Spirocyclisch metalloprotease inhibitoren
PL191366B1 (pl) 1996-09-10 2006-05-31 Vernalis Oxford Ltd Zastosowanie pochodnych kwasu hydroksamowego, pochodne kwasu hydroksamowego oraz kompozycje farmaceutyczne je zawierające
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
JP2001513484A (ja) 1997-07-31 2001-09-04 ザ プロクター アンド ギャンブル カンパニー 非環式メタロプロテアーゼ阻害剤
GB9810464D0 (en) * 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
JP2003506438A (ja) 1999-08-10 2003-02-18 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 抗菌剤
GB9929527D0 (en) * 1999-12-14 2000-02-09 Smithkline Beecham Plc Novel compounds
US6797820B2 (en) * 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
ATE360014T1 (de) 2001-06-15 2007-05-15 Vicuron Pharm Inc Bicyclische pyrrolidinverbindungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105789A (en) * 1976-05-10 1978-08-08 E. R. Squibb & Sons, Inc. Carboxyalkylacylamino acids
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4499079A (en) * 1982-11-18 1985-02-12 E. R. Squibb & Sons, Inc. Carboxy and substituted carboxy alkanoyl and cycloalkanoyl peptides
US4496540A (en) * 1982-12-30 1985-01-29 Biomeasure, Inc. Therapeutic compounds
JPS6115840A (ja) * 1984-07-03 1986-01-23 Microbial Chem Res Found 免疫賦活剤
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes

Also Published As

Publication number Publication date
DE69012575T2 (de) 1995-03-30
ES2063975T3 (es) 1995-01-16
DK0489032T3 (da) 1995-01-30
WO1991002716A3 (en) 1991-06-27
EP0489032B1 (en) 1994-09-14
JPH05501864A (ja) 1993-04-08
AU639706B2 (en) 1993-08-05
KR927003624A (ko) 1992-12-18
EP0489032A1 (en) 1992-06-10
US5910609A (en) 1999-06-08
CA2064786A1 (en) 1991-02-25
NZ235050A (en) 1991-12-23
NO920702L (no) 1992-04-23
GB8919251D0 (en) 1989-10-04
WO1991002716A2 (en) 1991-03-07
NO920702D0 (no) 1992-02-21
AU6045490A (en) 1991-04-03
TW202456B (ko) 1993-03-21
ATE111443T1 (de) 1994-09-15
DE69012575D1 (de) 1994-10-20
US5453438A (en) 1995-09-26
JP2871849B2 (ja) 1999-03-17

Similar Documents

Publication Publication Date Title
FI920771A0 (fi) Hydroxylamidbaserade kollagenasinhibitorer.
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
DE69734661D1 (de) Foerderung der wundheilung durch chemisch modifizierte tetracycline
SE9504661D0 (sv) New compounds
ES2148229T3 (es) Eteres y tioeteres en la posicion 17 de 4-aza-esteroides.
ES2063334T3 (es) Inhibidores de la colagenasa basados en el acido hidroxamico.
CY1110521T1 (el) Υποκατεστημενα ινδολια για τη διαμορφωση της nfkb-ενεργοτητας
ATE371457T1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
IT8268130A0 (it) Dispositivo per l applicazione di un campo elettromagnetico ad alta frequenza ad un tessuto vivente per favorirne la cicatrizzazione
ATE319447T1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
EP0832100A4 (en) NOVEL METALLOPROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND METHODS OF USE
ATE495187T1 (de) Dalda-analoge und ihre verwendung
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
EA199900542A1 (ru) Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида
DE69534908D1 (de) Verwendung von statin zur behandlung von hauterkrankungen
EA199700380A1 (ru) Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции
EA200000921A1 (ru) Антагонисты рецептора витронектина
DE69814394D1 (de) Verwendung von levobupivacain
ES2041705T3 (es) Procedimiento para la preparacion de 1-(4-hidroxi-3,5-di-terc-butil-benzoil)-homopiperazina y sus derivados.
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
SE9504662D0 (sv) New compounds
DE69419954T2 (de) Arzneimittel zur Behandlung von Hauterkrankungen
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11

Legal Events

Date Code Title Description
FD Application lapsed